Key Finding
Nearly one-third (28.2%) of children with irritable bowel syndrome experienced symptom improvement with placebo treatment, with the magnitude of response significantly influenced by dosing frequency, administration method, and outcome assessment approach.
Researchers analyzed 13 studies involving 445 children with irritable bowel syndrome (IBS) to understand how often placebo treatments—inactive substances with no therapeutic value—lead to symptom improvement. IBS is a common digestive disorder in children that causes abdominal pain, bloating, and changes in bowel habits. The study found that 28.2% of children receiving placebo treatments reported overall improvement in their symptoms, though only 5% experienced complete disappearance of abdominal pain. These findings are important because they reveal that nearly one in three children with IBS may feel better from placebo effects alone, which includes factors like increased attention from healthcare providers, expectation of improvement, and the natural fluctuation of symptoms over time. The researchers also discovered that certain factors influenced how strong the placebo effect was, including how often the treatment was given (less frequent dosing increased placebo response), the form of treatment (pills versus liquids), and who assessed the results (patients themselves versus medical professionals). While this study did not specifically examine acupuncture, understanding placebo responses is relevant for all IBS treatments in children. For families considering complementary therapies like acupuncture for pediatric IBS, these findings suggest that treatment effects should be evaluated carefully, considering that symptoms may improve regardless of the specific intervention used. If you're considering acupuncture for your child's IBS, seek a licensed acupuncturist with specialized training in pediatric care.
This meta-analysis of 13 randomized controlled trials examined placebo response rates in pediatric IBS, analyzing 445 patients in placebo groups. The pooled placebo response rate for overall improvement was 28.2% (95% CI, 16.6-39.9%), while complete abdominal pain resolution occurred in only 5% (95% CI, 0-18.4%). The placebo effect on abdominal pain scores showed a standardized mean difference of 0.675 (95% CI, 0.203-1.147). Significant moderators of placebo magnitude included mode of administration (P<0.01), dosing schedule (P<0.01), with less frequent dosing associated with higher placebo response, and clinical outcome assessor type (P=0.04), with patient-reported outcomes showing higher placebo rates than clinician-assessed measures. Clinical implications: When designing pediatric IBS trials or evaluating treatment efficacy in practice, clinicians should account for the substantial placebo response rate approaching 30%. This baseline improvement rate is relevant when assessing outcomes from any intervention, including acupuncture and other complementary therapies, emphasizing the need for rigorous comparative effectiveness research in this population.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.